N-methyl-2-(p-nitrophenoxy)ethylamine | 60814-17-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-methyl-2-(p-nitrophenoxy)ethylamine
• 英文别名: 4-Nitro-(2-methylaminoethoxy)benzene；N-methyl-2-(4-nitrophenoxy)ethanamine
• CAS: 60814-17-7
• 化学式: C₉H₁₂N₂O₃
• 分子量: 196.206
• InChiKey: SQWNEHIJLURBNR-UHFFFAOYSA-N

物化性质

• 熔点：
  33-34 °C
• 沸点：
  332.6±22.0 °C(Predicted)
• 密度：
  1.174±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  67.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-methyl-2-(p-nitrophenoxy)ethylamine 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 N-乙醇基-N-甲基-对硝基苯胺
  参考文献：
  名称：

  Knipe, Anthony C.; Sridhar, Narayan; Lound-Keast, Joseph, Journal of the Chemical Society. Perkin transactions II, 1984, p. 1893 - 1900

  摘要：

  DOI：
• 作为产物：
  描述：

  对硝基苯酚 在 sodium iodide 、 potassium carbonate 、 caesium carbonate 作用下， 以 氯化亚砜 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-methyl-2-(p-nitrophenoxy)ethylamine
  参考文献：
  名称：

  Substituted fused pyrroleoximes and fused pyrazoleoximes

  摘要：

  揭示了公式1的化合物及其药学上可接受的盐，其中R、Ar、A、n、R1和R2在此处定义。这些化合物是高度选择性的GABAA脑受体的激动剂、拮抗剂或逆拮抗剂，或者是GABAA脑受体的激动剂、拮抗剂或逆拮抗剂的前药，因此在焦虑、抑郁、唐氏综合症、睡眠和癫痫障碍、苯二氮卓类药物过量和增强记忆的诊断和治疗中非常有用。还披露了包括包装的药物组合物在内的药物组合物。

  公开号：

  US20020128236A1

文献信息

• Fused pyrrolecarboxamides: GABA brain receptor ligands
  申请人：Albaugh Pamela

  公开号：US20050014939A1

  公开（公告）日：2005-01-20

  Substituted pyrrolecarboxamide compounds are disclosed. These compounds are highly selective agonists, antagonists or inverse agonists for GABA A brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA A brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Alzheimer's dementia, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABA A receptors in tissue samples.

  揭示了取代吡咯甲酰胺化合物。这些化合物是高度选择性的GABAA脑受体的激动剂、拮抗剂或逆向激动剂，或者是GABAA脑受体的激动剂、拮抗剂或逆向激动剂的前药，因此在焦虑、抑郁、阿尔茨海默病痴呆、睡眠和癫痫障碍、苯二氮卓类药物过量以及增强记忆的诊断和治疗中非常有用。此外，还提供了包括包装的药物组合物在内的制药组合物。该发明的化合物还可用作定位组织样本中GABAA受体的探针。
• Substituted fused pyrroleoximes and fused pyrazoleoximes
  申请人：——

  公开号：US20020128236A1

  公开（公告）日：2002-09-12

  Disclosed are compounds of the formula 1 and the pharmaceutically acceptable salts thereof wherein R, Ar, A, n, R 1 and R 2 are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABA A brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA A brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are also disclosed.

  揭示了公式1的化合物及其药学上可接受的盐，其中R、Ar、A、n、R1和R2在此处定义。这些化合物是高度选择性的GABAA脑受体的激动剂、拮抗剂或逆拮抗剂，或者是GABAA脑受体的激动剂、拮抗剂或逆拮抗剂的前药，因此在焦虑、抑郁、唐氏综合症、睡眠和癫痫障碍、苯二氮卓类药物过量和增强记忆的诊断和治疗中非常有用。还披露了包括包装的药物组合物在内的药物组合物。
• fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
  申请人：Neurogen Corporation

  公开号：US05804686A1

  公开（公告）日：1998-09-08

  The present invention encompasses structures of the formula I: ##STR1## or the pharmaceutically acceptable non-toxic salts thereof wherein: G represents ##STR2## where Q is aryl substituents optionally mono or disubstituted with hydroxy or halogen; T is halogen, hydrogen, hydroxyl, amino or alkoxy having 1-6 carbon atoms; W is oxygen, nitrogen, sulfur, or optionally substituted methylene; X is hydrogen, hydroxyl, or alkyl; Z is an organic or inorganic substituent optionally forming a ring with subtituents on Q; ##STR3## independently represent optionally substituted carbon chains; wherein k, m, and n are independently 0, or an integer of from 1-3 R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are the same or different and represent organic or inorganic substituents. These compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors. These compounds are useful in the diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory.

  本发明涵盖了以下结构的化合物I：##STR1##或其药学上可接受的非毒性盐，其中：G代表##STR2##其中Q是芳基取代物，可选择地是单取代或二取代的羟基或卤素；T是卤素、氢、羟基、氨基或具有1-6个碳原子的烷氧基；W是氧、氮、硫或可选择地取代的亚甲基；X是氢、羟基或烷基；Z是有机或无机取代基，可选择地与Q上的取代基形成环；##STR3##独立地代表可选择地取代的碳链；其中k、m和n独立地为0，或为1-3的整数，R.sub.3、R.sub.4、R.sub.5和R.sub.6相同或不同，代表有机或无机取代基。这些化合物是高度选择性的GABAa脑受体的激动剂、拮抗剂或逆激动剂，或者是GABAa脑受体的激动剂、拮抗剂或逆激动剂的前药。这些化合物在焦虑、睡眠和癫痫障碍的诊断和治疗、苯二氮卓类药物过量和增强记忆方面是有用的。
• Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
  申请人：Neurogen Corporation

  公开号：US06211365B1

  公开（公告）日：2001-04-03

  Disclosed are compounds of the formula: or the pharmaceutically acceptable non-toxic salts thereof wherein: G, X, T, n, and R3-R6 are as defined herein, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors. These compounds are useful in the diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory.

  揭示的是以下化合物的结构式：或其药用可接受的无毒盐，其中：G、X、T、n 和 R3-R6 如本文所定义，这些化合物是高度选择性的 GABAa 大脑受体的激动剂、拮抗剂或逆向激动剂，或者是 GABAa 大脑受体的激动剂、拮抗剂或逆向激动剂的前药。这些化合物在焦虑、睡眠和癫痫障碍的诊断和治疗、苯二氮卓类药物过量和增强记忆方面具有用途。
• Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes
  申请人：Maynard George

  公开号：US20080032975A1

  公开（公告）日：2008-02-07

  Disclosed are compounds of the formula and the pharmaceutically acceptable salts thereof wherein R, Ar, A, n, R 1 and R 2 are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABA A brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA A brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are also disclosed.

  本发明涉及以下式的化合物及其药学上可接受的盐，其中R、Ar、A、n、R1和R2的定义如下。这些化合物是高度选择性的GABAA脑受体的激动剂、拮抗剂或反向激动剂，或者是GABAA脑受体激动剂、拮抗剂或反向激动剂的前药，因此可用于诊断和治疗焦虑症、抑郁症、唐氏综合征、睡眠和癫痫障碍、苯二氮卓类药物过量和增强记忆。还公开了包括包装的药物组合物在内的制药组合物。